Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: A positive correlation

Neuroscience Letters

Volumn 491, Issue 3, 2011, Pages 207-210

  Pedrini, Mariana ^a,b,c   Chendo, Inês ^a,d   Grande, Iria ^a,e   Lobato, Maria Ines ^a,c   Belmonte de Abreu, Paulo Silva ^a,b,c   Lersch, Camila ^a,b,c   Walz, Julio ^a,b,c   Kauer Sant'Anna, Márcia ^a,b,c   Kapczinski, Flavio ^a,b,c   Gama, Clarissa Severino ^a,b,c  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b Universidade Federal do Rio Grande do Sul ^*  (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d HOSPITAL DE SANTA MARIA   (Portugal)

^e UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Antipsychotics; Brain derived neurotrophic factor; Clozapine; Cognitive functioning; Schizophrenia

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITION; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CLOZAPINE; FEMALE; HUMANS; MALE; SCHIZOPHRENIA;

EID: 79951773515     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.01.039     Document Type: Article

References (37)

1. Bai O., Chlan-Fourney J., Bowen R., Keegan D., Li X.M. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J. Neurosci. Res. 2003, 71(1):127-131.
2. Baig B.J., Whalley H.C., Hall J., Mcintosh A.M., Job D.E., Cunningham-Owens D.G., Johnstone E.C., Lawrie S.M. Functional magnetic resonance imaging of BDNF val66met polymorphism in unmedicated subjects at high genetic risk of schizophrenia performing a verbal memory task. Psychiatry Res. 2010, 183(3):195-2001.
3. Bekinschtein P., Cammarota M., Katche C., Slipczuk L., Rossato J.I., Goldin A., Izquierdo I.J., Medina H. BDNF is essential to promote persistence of long-term memory storage. Proc. Natl. Acad. Sci. U.S.A. 2008, 105(7):2711-2716.
4. Buckley P.F., Pillai A., Evans D., Stirewalt E., Mahadik S. Brain derived neurotrophic factor in first-episode psychosis. Schizophr. Res. 2007, 91(1-3):1-5.
5. Carlino D., Leone E., Di Cola F., Baj G., Marin R., Dinelli G., Tongiorgi E., De Vanna M. Low serum truncated-BDNF isoform correlates with higher cognitive impairment in schizophrenia. J. Psychiatr. Res. 2011, 45(2):273-279.
6. Craddock M., Asherson P., Owen M.J., Williams J., McGuffin P., Farmer A.E. Concurrent validity of the OPCRIT diagnoses with consensus best-estimate lifetime diagnoses. Br. J. Psychiatry 1996, 169(1):58-63.
7. de Lucena D., Fernades B.S., Berk M., Doss S., Medeiros D.W., Pedrini M., Kunz M., Gomes F.A., Giglio L.F., Lobato M.I., Belmonte-de-Abreu P.S., Gama C.S. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J. Clin. Psychiatry 2009, 70(10):1416-1423.
8. de Lucena D., Fernandes B.S., Kunz M., Fries G.R., Stertz L., Aguiar B., Pfaffenseller B., Gama C.S. Lack of association between serum brain-derived neurotrophic factor levels and improvement of schizophrenia symptoms in a double-blind, randomized, placebo-controlled trial of memantine as adjunctive therapy to clozapine. J. Clin. Psychiatry 2010, 71(1):91-92.
9. Dias V.V., Brissos S.B., Frey N., Andreazza A.C., Cardoso C., Kapczinski F. Cognitive function and serum levels of brain-derived neurotrophic factor in patients with bipolar disorder. Bipolar Disord. 2009, 11(6):663-671.
10. Gama S.C., Andreazza A.C., Kunz M., Berk M., Belmonte-de-Abreu P.S., Kapczinski F. Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci. Lett. 2007, 420(1):45-48.
11. Gama C.S., Berk M., Andreazza A.C., Kapczinski F., Belmonte-de-Abreu P.S. Serum levels of brain-derived neurotrophic factor and thiobarbituric acid reactive substances in chronically medicated schizophrenic patients: a positive correlation. Rev. Bras. Psiquiatr. 2008, 30(4):337-340.
12. Gama C.S., Salvador M., Andreazza A.C., Kapczinski F., Belmonte-de-Abreu P.S. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30(3):512-515.
13. Gama C.S., Salvador M., Andreazza A.C., Lobato M.I., Berk M., Kapczinski F., Belmonte-de-Abreu P.S. Elevated serum thiobarbituric acid reactive substances in clinically symptomatic schizophrenic males. Neurosci. Lett. 2008, 433(3):270-273.
14. Green A.I., Tohen M., Patel J.K., Banov M., DuRand C., Berman I., Chang H., Zarate C., Posener J., Lee H., Dawson R., Richards C., Cole J.O., Schatzberg A.F. Clozapine in the treatment of refractory psychotic mania. Am. J. Psychiatry 2000, 157(6):982-986.
15. M.J. Green, S.L. Matheson, A. Shepherd, C.S. Weickert, V.J. Carr, Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis, Mol. Psychiatry 24, in press, doi:10.1038/mp.2010.88.
16. Grillo R.W., Ottoni G.L., Leke R., Souza D.O., Portela L.V., Lara D.R. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J. Psychiatr. Res. 2007, 41(1-2):31-35.
17. Guimarães L.R., Jacka F.N., Gama S.C., Berk M., Leitão-Azevedo C.L., Belmonte-de-Abreu M.G., Lobato M.I., Andreazza A.C., Ceresér K.M., Kapczinski F., Belmonte-de-Abreu P. Serum levels of brain-derived neurotrophic factor in schizophrenia on a hypocaloric diet. Prog. Neupsychopharmacol. Biol. Psychiatry 2008, 32(6):1595-1598.
18. Jindal R.D., Pillai A.K., Mahadik S.P., Eklund K., Montrose D.M., Keshavan M.S. Decreased BDNF in patients with antipsychotic naïve first episode schizophrenia. Schizophr. Res. 2010, 119(1-3):47-51.
19. Lieberman J.A. Pathophysiologic mechanism in the pathogenesis and clinical course of schizophrenia. J. Clin. Psychiatry 1999, 60(Suppl 12):9-12.
20. Manschreck T.C., Redmond D.A., Candela S.F., Maher B.A. Effects of clozapine on psychiatric symptoms, cognition, and functional outcome in schizophrenia. J. Neuropsychiatry Clin. Neurosci. 1999, 11:481-489.
21. McGurk S.R. The effects of clozapine on cognitive functioning in schizophrenia. J. Clin. Psychiatry 1999, 60(Suppl. 12):24-29.
22. Molina V., Tamayo P., Montes C., De Luxán A., Martins C., Rivas N., Sancho C., Dominguez-Gil A. Clozapine may partially compensate for task-related brain perfusion abnormalities in risperidone-resistant schizophrenia patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(4):948-954.
23. Palomino A., Vallejo-Illarramendi A., Gonzalez-Pinto A., Aldama A., Gonzalez-Gomez C., Mosquera F., Gonzalez-Garcia G., Matute C. Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorders patients. Schizophr. Res. 2006, 86(1-3):321-322.
24. Pirildar S., Gonul A.S., Taneli F., Akdeniz F. Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28(4):709-713.
25. Post R.M. Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications. J. Psychiatr. Res. 2007, 41(12):979-990.
26. Rajji T.K., Uchida H., Ismail Z., Ng W., Mamo D.C., Remington G., Pollock B.G., Mulsant B.H. Clozapine and global cognition in schizophrenia. J. Clin. Psychopharmacol. 2010, 30(4):431-436.
27. Rapoport J.L., Addington A., Frangou S. The neurodevelopmental model of schizophrenia: what can very early onset cases tell us?. Curr. Psychiatry Rep. 2005, 7(2):81-82.
28. Rizos E.N., Michalopoulou P.G., Siafakas N., Stefanis N., Douzenis A., Rontos I., Laskos E., Kastania A., Zoumpourlis V., Lykouras L. Association of serum brain-derived neurotrophin factor and duration of untreated psychosis in first-episode patients with schizophrenia. Neuropsychobiology 2010, 62(2):87-90.
29. Rizos E.N., Rontos I., Laskos E., Arsenis G., Michalopoulou P.G., Vasilopoulos D., Gournellis R., Lykouras L. Investigation of serum BDNF levels in drug-naïve patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(5):1308-1311.
30. Romano F., Elkis H. Tradução e Adaptação de um Instrumento de Avaliação Psicopatológica das Psicoses: a Escala Breve de Avaliação Psiquiátrica. Versão Ancorada (BPRS-A). J. Bras. Psiquiatr. 1996, 45:43-49.
31. Stip E. Cognition schizophrenia and the effect of antipsychotics. Encephale 2006, 32(3):341-350. Pt 1.
32. Tan Y.L., Zhou D.F., Cao L.Y., Zou Y.Z., Zhang X.Y. Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci. Lett. 2005, 382(1-2):27-32.
33. Toyooka K., Asama K., Watanabe Y., Murakate T., Takahashi M., Someya T., Nawa H. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res. 2002, 110(3):249-257.
34. Vinogradov S., Fisher M., Holland C., Shelly W., Wolkowitz O., Mellon S.H. Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia?. Biol. Psychiatry 2009, 66(6):549-553.
35. Weickert C.S., Hyde T.M., Lipska B.K., Herman M.M., Weinberger D.R., Kleinman J.E. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol. Psychiatry 2003, 8(6):592-610.
36. Xiu M.H., Hui L., Dang Y.F., Hou T.D., Zhang C.X., Zheng Y.L., da Chen C., Kosten T.R., Zhang X.Y. Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with antipsychotics. Progr. Neuropsychopharmacol. Biol. Psychiatry 2009, 33(8):1508-1512.
37. Zhao J., He X., Liu Z., Yang D. The effects of clozapine on cognitive function and regional cerebral blood flow in the negative symptom profile schizophrenia. Int. J. Psychiatry Med. 2006, 36(2):171-181.